Glucagon-like Peptide-1 Receptor Agonists in the Context of Pathophysiology of Diverse Heart Failure with Preserved Ejection Fraction Phenotypes: Potential Benefits and Mechanisms of Action

被引:0
作者
Bykova, Aleksandra [1 ,2 ]
Serova, Maria [1 ,3 ]
Chashkina, Maria [1 ]
Kosharnaya, Raisa [4 ]
Salpagarova, Zukhra [5 ]
Andreev, Denis [1 ]
Giverts, Ilya [6 ,7 ]
机构
[1] Sechenov Univ, IM Sechenov First Moscow State Med Univ, NV Sklifosovsky Inst Clin Med, Dept Cardiol Funct & Ultrasound Diagnost, Bolshaya Pirogovskaya St 6-1, Moscow 119991, Russia
[2] Russian Acad Sci, Sci Res Inst Syst Anal, Dept Med Informat, Moscow, Russia
[3] City Clin Hosp 1, Moscow State Healthcare Inst, Dept Surg Treatment Complex Rhythm Disorders & Pac, Moscow, Russia
[4] Endocrinol Res Ctr, Dept Cardiol & Vasc Surg, Moscow, Russia
[5] Med Ctr ATLAS, Dept Cardiol, Moscow, Russia
[6] Maimonides Hosp, Dept Internal Med, New York, NY USA
[7] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA USA
关键词
Glucagon-like peptide-1 receptor agonists; heart failure with preserved ejection fraction; diabetes; obesity; atrial fibrillation; coronary artery; disease; arterial hypertension; TYPE-2; DIABETES-MELLITUS; MAJOR CARDIOVASCULAR EVENTS; GLUCOSE-LOWERING AGENTS; GLP-1; RECEPTOR; ATRIAL-FIBRILLATION; DOUBLE-BLIND; CONTROLLED-TRIAL; ADIPOSE-TISSUE; LIRAGLUTIDE; EXENATIDE;
D O I
10.15420/cfr.2024.06
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This review examines the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on different heart failure phenotypes with preserved ejection fraction (HFpEF). Traditional heart failure treatment modalities have shown limited success in improving outcomes for patients with HFpEF, but new evidence suggests that GLP-1RAs could be beneficial. The positive effects of GLP-1RAs are likely due to their ability to reduce systemic inflammation, enhance metabolism and directly affect the cardiovascular system, addressing critical aspects of HFpEF pathology. However, the exact impact of GLP-1RAs on clinical outcomes for different HFpEF phenotypes is still unclear. This review highlights both the potential benefits and the current limitations of GLP-1RA therapy, suggesting a careful approach for their application in clinical practice.
引用
收藏
页数:8
相关论文
共 82 条
  • [61] The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
    Secher, Anna
    Jelsing, Jacob
    Baquero, Arian F.
    Hecksher-Sorensen, Jacob
    Cowley, Michael A.
    Dalboge, Louise S.
    Hansen, Gitte
    Grove, Kevin L.
    Pyke, Charles
    Raun, Kirsten
    Schaffer, Lauge
    Tang-Christensen, Mads
    Verma, Saurabh
    Witgen, Brent M.
    Vrang, Niels
    Knudsen, Lotte Bjerre
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (10) : 4473 - 4488
  • [62] Recent updates on GLP-1 agonists: Current advancements & challenges
    Sharma, Dilip
    Verma, Suril
    Vaidya, Shivani
    Kalia, Kiran
    Tiwari, Vinod
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2018, 108 : 952 - 962
  • [63] Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: A network meta-analysis
    Shi, Wence
    Zhang, Wenchang
    Zhang, Da
    Ren, Ge
    Wang, Pengfei
    Gao, Lihua
    Chen, Haonan
    Ding, Chunhua
    [J]. HEART RHYTHM, 2021, 18 (07) : 1090 - 1096
  • [64] The effect of glucagon-like peptide 1 on cardiovascular risk
    Sivertsen, Jacob
    Rosenmeier, Jaya
    Holst, Jens J.
    Vilsboll, Tina
    [J]. NATURE REVIEWS CARDIOLOGY, 2012, 9 (04) : 209 - 222
  • [65] Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men
    Skov, Jeppe
    Dejgaard, Anders
    Frokiaer, Jorgen
    Holst, Jens Juul
    Jonassen, Thomas
    Rittig, Soren
    Christiansen, Jens Sandahl
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (04) : E664 - E671
  • [66] Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
    Solomon, S. D.
    McMurray, J. J., V
    Claggett, B.
    de Boer, R. A.
    DeMets, D.
    Hernandez, A. F.
    Inzucchi, S. E.
    Kosiborod, M. N.
    Lam, C. S. P.
    Martinez, F.
    Shah, S. J.
    Desai, A. S.
    Jhund, P. S.
    Belohlavek, J.
    Chiang, C-E
    Borleffs, C. J. W.
    Comin-Colet, J.
    Dobreanu, D.
    Drozdz, J.
    Fang, J. C.
    Alcocer-Gamba, M. A.
    Al Habeeb, W.
    Han, Y.
    Cabrera Honorio, J. W.
    Janssens, S. P.
    Katova, T.
    Kitakaze, M.
    Merkely, B.
    O'Meara, E.
    Saraiva, J. F. K.
    Tereshchenko, S. N.
    Thierer, J.
    Vaduganathan, M.
    Vardeny, O.
    Verma, S.
    Pham, V. N.
    Wilderang, U.
    Zaozerska, N.
    Bachus, E.
    Lindholm, D.
    Petersson, M.
    Langkilde, A. M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, : 1089 - 1098
  • [67] Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
    Stratton, IM
    Adler, AI
    Neil, HAW
    Matthews, DR
    Manley, SE
    Cull, CA
    Hadden, D
    Turner, RC
    Holman, RR
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7258): : 405 - 412
  • [68] Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits
    Sudo, Mitsumasa
    Li, Yuxin
    Hiro, Takafumi
    Takayama, Tadateru
    Mitsumata, Masako
    Shiomi, Masashi
    Sugitani, Masahiko
    Matsumoto, Taro
    Hao, Hiroyuki
    Hirayama, Atsushi
    [J]. ATHEROSCLEROSIS, 2017, 265 : 283 - 291
  • [69] Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
    Sun, Feng
    Wu, Shanshan
    Wang, Jing
    Guo, Shuxia
    Chai, Sanbao
    Yang, Zhirong
    Li, Lishi
    Zhang, Yuan
    Ji, Linong
    Zhan, Siyan
    [J]. CLINICAL THERAPEUTICS, 2015, 37 (01) : 225 - 241
  • [70] Study of the Potential Association of Adipose Tissue GLP-1 Receptor with Obesity and Insulin Resistance
    Vendrell, Joan
    El Bekay, Rajaa
    Peral, Belen
    Garcia-Fuentes, Eduardo
    Megia, Anna
    Macias-Gonzalez, Manuel
    Fernandez Real, Jose
    Jimenez-Gomez, Yolanda
    Escote, Xavier
    Pachon, Gisela
    Simo, Rafael
    Selva, David M.
    Malagon, Maria M.
    Tinahones, Francisco J.
    [J]. ENDOCRINOLOGY, 2011, 152 (11) : 4072 - 4079